Highlights of weekly biotech stock moves

AB Science S.A. (Euronext:AB) was up €0.29 to €11.32 on Friday after EMA's CHMP reiterated its recommendation against conditional approval of Masiviera masitinib for first-line treatment of non-resectable locally advanced or metastatic pancreatic cancer in combination with gemcitabine. The company said it plans to resubmit the MAA and seek full approval with data from a planned Phase III confirmatory trial; data are expected in 2H17.

AB Science was off €0.15 last week...